Current Osteoporosis Reports

, Volume 8, Issue 2, pp 84–90 | Cite as

PPARs in Bone: The Role in Bone Cell Differentiation and Regulation of Energy Metabolism



Obesity, diabetes, and osteoporosis are major public health concerns. Current estimates indicate that the US population consists of 25% obese, 30% diabetic and prediabetic, and, among the elderly, 50% of all osteoporotic individuals. Mechanistically, these pathologies share several features including common regulators of bone homeostasis and energy metabolism. Peroxisome proliferator-activated receptors (PPARs) represent a family of proteins that control energy turnover in adipose, liver, and muscle tissue. These proteins also control bone turnover and regulate bone cell differentiation. Recent evidence suggests that bone is an organ integral to energy metabolism not only with respect to energy storage, but also as an organ regulating systemic energy homeostasis. In this article, we review current knowledge on the role of PPARs in bone metabolism and bone cell differentiation. We also discuss the role of bone fat in modulation of bone marrow microenvironment and its possible contribution to the systemic regulation of energy metabolism.


Bone metabolism Bone cell differentiation PPARs Energy metabolism Mesenchymal stem cells Thiazolidinediones 


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • Lee NK, Sowa H, Hinoi E, et al.: Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456–469. This study demonstrates for the first time that bone-derived osteocalcin hormone regulates energy metabolism.CrossRefPubMedGoogle Scholar
  2. 2.
    Hinoi E, Gao N, Jung DY, et al.: An osteoblast-dependent mechanism contributes to the leptin regulation of insulin secretion. Ann N Y Acad Sci 2009, 1173(Suppl 1):E20–E30.CrossRefPubMedGoogle Scholar
  3. 3.
    Bianco P, Riminucci M, Gronthos S, Robey PG: Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 2001, 19:180–192.CrossRefPubMedGoogle Scholar
  4. 4.
    Lecka-Czernik B, Suva LJ: Resolving the two “bony” faces of PPAR-gamma. PPAR Res 2006, 2006:27489.Google Scholar
  5. 5.
    Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat Med 2004, 10:355–361.CrossRefPubMedGoogle Scholar
  6. 6.
    Zoete V, Grosdidier A, Michielin O: Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 2007, 1771:915–925.PubMedGoogle Scholar
  7. 7.
    Tontonoz P, Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289–312.CrossRefPubMedGoogle Scholar
  8. 8.
    Heikkinen S, Auwerx J, Argmann CA: PPARgamma in human and mouse physiology. Biochim Biophys Acta 2007, 1771:999–1013.PubMedGoogle Scholar
  9. 9.
    Ren D, Collingwood TN, Rebar EJ, et al.: PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 2002, 16:27–32.CrossRefPubMedGoogle Scholar
  10. 10.
    Lecka-Czernik B, Gubrij I, Moerman EA, et al.: Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR-gamma 2. J Cell Biochem 1999, 74:357–371.CrossRefPubMedGoogle Scholar
  11. 11.
    Willson TM, Lambert MH, Kliewer SA: Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001, 70:341–367.CrossRefPubMedGoogle Scholar
  12. 12.
    Knouff C, Auwerx J: Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 2004, 25:899–918.CrossRefPubMedGoogle Scholar
  13. 13.
    Lecka-Czernik B, Moerman EJ, Grant DF, et al.: Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002, 143:2376–2384.CrossRefPubMedGoogle Scholar
  14. 14.
    Wan Y, Chong LW, Evans RM: PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007, 13:1496–1503.CrossRefPubMedGoogle Scholar
  15. 15.
    Rzonca SO, Suva LJ, Gaddy D, et al.: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401–406.CrossRefPubMedGoogle Scholar
  16. 16.
    • Lazarenko OP, Rzonca SO, Hogue WR, et al.: Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007, 148:2669–2680. This article shows that aging is a confounding factor for rosiglitazone-induced bone loss in mice.CrossRefPubMedGoogle Scholar
  17. 17.
    Akune T, Ohba S, Kamekura S, et al.: PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004, 113:846–855.PubMedGoogle Scholar
  18. 18.
    Rosen CJ, Bouxsein ML: Mechanism of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006, 2:35–43.CrossRefPubMedGoogle Scholar
  19. 19.
    Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B: Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004, 3:379–389.CrossRefPubMedGoogle Scholar
  20. 20.
    Spiteller G: The important role of lipid peroxidation processes in aging and age dependent diseases. Mol Biotechnol 2007, 37:5–12.CrossRefPubMedGoogle Scholar
  21. 21.
    Maurin AC, Chavassieux PM, Vericel E, Meunier PJ: Role of polyunsaturated fatty acids in the inhibitory effect of human adipocytes on osteoblastic proliferation. Bone 2002, 31:260–266.CrossRefPubMedGoogle Scholar
  22. 22.
    • Shockley KR, Rosen CJ, Churchill GA, Lecka-Czernik B: PPARγ2 regulates a molecular signature of marrow mesenchymal stem cells. PPAR Research 2007, 2007:81219. This article demonstrates that PPAR-γ2 plays a major role in regulation of MSC "stemness" phenotype.CrossRefPubMedGoogle Scholar
  23. 23.
    Minaire P, Edouard C, Arlot M, Meunier PJ: Marrow changes in paraplegic patients. Calcif Tissue Int 1984, 36:338–340.CrossRefPubMedGoogle Scholar
  24. 24.
    Trudel G, Payne M, Madler B, et al.: Bone marrow fat accumulation after 60 days of bed rest persisted 1 year after activities were resumed along with hemopoietic stimulation: the Women International Space Simulation for Exploration study. J Appl Physiol 2009, 107:540–548.CrossRefPubMedGoogle Scholar
  25. 25.
    Suva LJ, Gaddy D, Perrien DS, et al.: Regulation of bone mass by mechanical loading: microarchitecture and genetics. Curr Osteoporos Rep 2005, 3:46–51.CrossRefPubMedGoogle Scholar
  26. 26.
    Marie PJ, Kaabeche K: PPAR gamma and control of bone mass in skeletal unloading. PPAR Res 2006, 2006:64807.PubMedGoogle Scholar
  27. 27.
    Cock TA, Back J, Elefteriou F, et al.: Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 2004, 5:1007–1012.CrossRefPubMedGoogle Scholar
  28. 28.
    Ali AA, Weinstein RS, Stewart SA, et al.: Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005, 146:1226–1235.CrossRefPubMedGoogle Scholar
  29. 29.
    Sottile V, Seuwen K, Kneissel M: Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004, 75:329–337.CrossRefPubMedGoogle Scholar
  30. 30.
    Modder UI, Monroe DG, Fraser DG, et al.: Skeletal consequences of deletion of steroid receptor coactivator-2/transcription intermediary factor-2. J Biol Chem 2009, 284:18767–18777.CrossRefPubMedGoogle Scholar
  31. 31.
    • Shockley KR, Lazarenko OP, Czernik PJ, et al.: PPARγ2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009, 106:232–246. This article provides an extensive analysis of the effect of rosiglitazone on gene expression in marrow MSCs.CrossRefPubMedGoogle Scholar
  32. 32.
    Lecka-Czernik B: Bone as a target of type 2 diabetes treatment. Curr Opin Investig Drugs 2009, 10:1085–1090.PubMedGoogle Scholar
  33. 33.
    • Kahn SE, Zinman B, Lachin JM, et al.: Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845–851. This article provides a retrospective analysis of fracture risk and type of fractures among the ADOPT participants.CrossRefPubMedGoogle Scholar
  34. 34.
    • Loke YK, Singh S, Furberg CD: Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009, 180:32–39. This article provides a comprehensive review of available clinical trials in respect to the effect of TZDs on risk of fractures.PubMedGoogle Scholar
  35. 35.
    Meier C, Kraenzlin ME, Bodmer M, et al.: Use of thiazolidinediones and fracture risk. Arch Intern Med 2008, 168:820–825.CrossRefPubMedGoogle Scholar
  36. 36.
    Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006, 116:571–580.CrossRefPubMedGoogle Scholar
  37. 37.
    Remick J, Weintraub H, Setton R, et al.: Fibrate therapy: an update. Cardiol Rev 2008, 16:129–141.Google Scholar
  38. 38.
    Giaginis C, Tsantili-Kakoulidou A, Theocharis S: Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol 2007, 21:231–244.CrossRefPubMedGoogle Scholar
  39. 39.
    Wu X, Peters JM, Gonzalez FJ, et al.: Frequency of stromal lineage colony forming units in bone marrow of peroxisome proliferator-activated receptor-alpha-null mice. Bone 2000, 26:21–26.CrossRefPubMedGoogle Scholar
  40. 40.
    Yang Q, Gonzalez FJ: Peroxisome proliferator-activated receptor alpha regulates B lymphocyte development via an indirect pathway in mice. Biochem Pharmacol 2004, 68:2143–2150.CrossRefPubMedGoogle Scholar
  41. 41.
    Still K, Grabowski P, Mackie I, et al.: The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int 2008, 83:285–292.CrossRefPubMedGoogle Scholar
  42. 42.
    Chan BY, Gartland A, Wilson PJ, et al.: PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 2007, 40:149–159.CrossRefPubMedGoogle Scholar
  43. 43.
    Syversen U, Stunes AK, Gustafsson BI, et al.: Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 2009, 9:10.CrossRefPubMedGoogle Scholar
  44. 44.
    Meier CR, Schlienger RG, Kraenzlin ME, et al.: HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000, 283:3205–3210.CrossRefPubMedGoogle Scholar
  45. 45.
    Barish GD, Narkar VA, Evans RM: PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006, 116:590–597.CrossRefPubMedGoogle Scholar
  46. 46.
    Wang YX, Lee CH, Tiep S, et al.: Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159–170.CrossRefPubMedGoogle Scholar
  47. 47.
    Gimble JM, Zvonic S, Floyd ZE, et al.: Playing with bone and fat. J Cell Biochem 2006, 98:251–266.CrossRefPubMedGoogle Scholar
  48. 48.
    Tavassoli M: Marrow adipose cells and hemopoiesis: an interpretative review. Exp Hematol 1984, 12:139–146.PubMedGoogle Scholar
  49. 49.
    Elefteriou F, Ahn JD, Takeda S, et al.: Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005, 434:514–520.CrossRefPubMedGoogle Scholar
  50. 50.
    Shinoda Y, Yamaguchi M, Ogata N, et al.: Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006, 99:196–208.CrossRefPubMedGoogle Scholar
  51. 51.
    Cartwright MJ, Tchkonia T, Kirkland JL: Aging in adipocytes: potential impact of inherent, depot-specific mechanisms. Exp Gerontol 2007, 42:463–471.CrossRefPubMedGoogle Scholar
  52. 52.
    Gasparrini M, Rivas D, Elbaz A, Duque G: Differential expression of cytokines in subcutaneous and marrow fat of aging C57BL/6 J mice. Exp Gerontol 2009, 44:613–618.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Departments of Orthopaedic Surgery and Physiology and Pharmacology, Center for Diabetes and Endocrine ResearchUniversity of Toledo Medical CenterToledoUSA

Personalised recommendations